HUE070208T2 - G-fehérjéhez kapcsolt receptor (GPCR) moduláció imipridonokkal - Google Patents
G-fehérjéhez kapcsolt receptor (GPCR) moduláció imipridonokkalInfo
- Publication number
- HUE070208T2 HUE070208T2 HUE17745078A HUE17745078A HUE070208T2 HU E070208 T2 HUE070208 T2 HU E070208T2 HU E17745078 A HUE17745078 A HU E17745078A HU E17745078 A HUE17745078 A HU E17745078A HU E070208 T2 HUE070208 T2 HU E070208T2
- Authority
- HU
- Hungary
- Prior art keywords
- imipridones
- gpcr
- modulation
- protein
- coupled receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/015817 WO2016123571A1 (en) | 2015-01-30 | 2016-01-29 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
| US201662308325P | 2016-03-15 | 2016-03-15 | |
| US201662425403P | 2016-11-22 | 2016-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE070208T2 true HUE070208T2 (hu) | 2025-05-28 |
Family
ID=59398848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17745078A HUE070208T2 (hu) | 2016-01-29 | 2017-01-30 | G-fehérjéhez kapcsolt receptor (GPCR) moduláció imipridonokkal |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11116771B2 (enExample) |
| EP (2) | EP4524567A3 (enExample) |
| JP (3) | JP7030701B2 (enExample) |
| KR (2) | KR20250065717A (enExample) |
| CN (2) | CN115844895B (enExample) |
| AU (2) | AU2017211423B2 (enExample) |
| BR (1) | BR112018015590A2 (enExample) |
| CA (2) | CA3294566A1 (enExample) |
| DK (1) | DK3408298T3 (enExample) |
| ES (1) | ES3012491T3 (enExample) |
| FI (1) | FI3408298T3 (enExample) |
| HR (1) | HRP20250207T1 (enExample) |
| HU (1) | HUE070208T2 (enExample) |
| IL (3) | IL316540A (enExample) |
| LT (1) | LT3408298T (enExample) |
| MA (1) | MA43879B1 (enExample) |
| MX (2) | MX2018009227A (enExample) |
| NZ (1) | NZ745425A (enExample) |
| PL (1) | PL3408298T3 (enExample) |
| PT (1) | PT3408298T (enExample) |
| RS (1) | RS66519B1 (enExample) |
| SG (2) | SG10202108306UA (enExample) |
| SI (1) | SI3408298T1 (enExample) |
| SM (1) | SMT202500086T1 (enExample) |
| WO (1) | WO2017132661A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017132661A2 (en) * | 2016-01-29 | 2017-08-03 | Oncoceutics, Inc. | G protein-coupled receptor (gpcr) modulation by imipridones |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| EP3682035B1 (en) * | 2017-09-15 | 2025-02-05 | The Regents of the University of California | Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring |
| US11674963B2 (en) | 2017-09-27 | 2023-06-13 | The Regents Of The University Of California | GPCRs in cancer-associated fibroblasts |
| EP3745862B1 (en) | 2018-01-31 | 2024-06-26 | Mayo Foundation for Medical Education and Research | D1 dopamine receptor agonists for treating fibrotic pathologies |
| KR20200141080A (ko) * | 2018-04-09 | 2020-12-17 | 오르제네시스 인코포레이티드 | 바이옥솜 입자, 레독솜, 방법 및 조성물 |
| CN109157656B (zh) * | 2018-10-15 | 2021-08-27 | 重庆医科大学附属永川医院 | 一种双靶标肿瘤疫苗及其制备方法和应用 |
| WO2020172485A1 (en) * | 2019-02-22 | 2020-08-27 | Board Of Regents, The University Of Texas System | Methods of using imipridones |
| EP4003348B1 (en) | 2019-07-30 | 2024-04-03 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating fibrotic pathologies |
| KR102403686B1 (ko) | 2020-05-15 | 2022-05-31 | 뉴로핏 주식회사 | 뇌자극 위치 제공장치 및 방법 |
| BR112023002082A2 (pt) | 2020-08-06 | 2023-05-09 | Eoetvoes Lorand Tudomanyegyetem | Síntese de derivados de imipridona e sua avaliação para sua atividade anticancerígena |
| CN112402439A (zh) * | 2020-11-18 | 2021-02-26 | 西安组织工程与再生医学研究所 | miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用 |
| US11648248B1 (en) | 2022-01-12 | 2023-05-16 | King Abdulaziz University | Potent antimicrobial compounds with a pyridazine nucleus |
| EP4565718A4 (en) * | 2022-08-03 | 2026-08-05 | Xiandong Shi | QUANTITATIVE METHOD FOR DETERMINING A MENTAL STATE BASED ON DRD1 AND/OR DRD5, AND ITS APPLICATION |
| CN115531378B (zh) * | 2022-10-19 | 2023-10-13 | 中国医学科学院医药生物技术研究所 | Pht427作为ndm-1与kpc-2双重抑制剂的应用 |
| WO2024157207A1 (en) * | 2023-01-25 | 2024-08-02 | Gpcr Therapeutics, Inc. | Gpcr inhibitors and uses thereof |
| EP4698146A1 (en) * | 2023-04-20 | 2026-02-25 | Institut Gustave-Roussy | Liquid and solid compositions of imipridone derivatives |
| CN116731136B (zh) * | 2023-08-04 | 2023-12-05 | 齐鲁工业大学(山东省科学院) | H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004082570A2 (en) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
| US20070026402A1 (en) * | 2003-07-08 | 2007-02-01 | Noble Ernest P | Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof |
| US8088895B2 (en) * | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| AU2008302345A1 (en) | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
| AU2012222812A1 (en) | 2011-02-28 | 2013-05-02 | Mcmaster University | Treatment of cancer with dopamine receptor antagonists |
| RS67757B1 (sr) | 2011-04-29 | 2026-03-31 | Penn State Res Found | Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija |
| WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| US9688679B2 (en) | 2013-03-13 | 2017-06-27 | Oncoceutics, Inc. | 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy |
| US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| PL2968294T3 (pl) | 2013-03-13 | 2019-10-31 | Oncoceutics Inc | 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu |
| SMT201900291T1 (it) * | 2013-11-15 | 2019-07-11 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso |
| HUE069651T2 (hu) * | 2014-03-31 | 2025-03-28 | Scripps Research Inst | Farmakofór TRAIL indukcióra |
| SMT202500087T1 (it) * | 2015-01-30 | 2025-03-12 | Oncoceutics Inc | Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia |
| CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| WO2017132661A2 (en) * | 2016-01-29 | 2017-08-03 | Oncoceutics, Inc. | G protein-coupled receptor (gpcr) modulation by imipridones |
| US10172862B2 (en) | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
-
2017
- 2017-01-30 WO PCT/US2017/015608 patent/WO2017132661A2/en not_active Ceased
- 2017-01-30 HR HRP20250207TT patent/HRP20250207T1/hr unknown
- 2017-01-30 CA CA3294566A patent/CA3294566A1/en active Pending
- 2017-01-30 PT PT177450780T patent/PT3408298T/pt unknown
- 2017-01-30 LT LTEPPCT/US2017/015608T patent/LT3408298T/lt unknown
- 2017-01-30 IL IL316540A patent/IL316540A/en unknown
- 2017-01-30 CN CN202211658374.3A patent/CN115844895B/zh active Active
- 2017-01-30 RS RS20250172A patent/RS66519B1/sr unknown
- 2017-01-30 EP EP24210288.7A patent/EP4524567A3/en active Pending
- 2017-01-30 FI FIEP17745078.0T patent/FI3408298T3/fi active
- 2017-01-30 PL PL17745078.0T patent/PL3408298T3/pl unknown
- 2017-01-30 DK DK17745078.0T patent/DK3408298T3/da active
- 2017-01-30 SI SI201731593T patent/SI3408298T1/sl unknown
- 2017-01-30 ES ES17745078T patent/ES3012491T3/es active Active
- 2017-01-30 EP EP17745078.0A patent/EP3408298B1/en active Active
- 2017-01-30 CN CN201780015327.8A patent/CN109311980B/zh active Active
- 2017-01-30 AU AU2017211423A patent/AU2017211423B2/en active Active
- 2017-01-30 NZ NZ745425A patent/NZ745425A/en unknown
- 2017-01-30 HU HUE17745078A patent/HUE070208T2/hu unknown
- 2017-01-30 SG SG10202108306UA patent/SG10202108306UA/en unknown
- 2017-01-30 JP JP2018540011A patent/JP7030701B2/ja active Active
- 2017-01-30 US US16/073,228 patent/US11116771B2/en active Active
- 2017-01-30 MA MA43879A patent/MA43879B1/fr unknown
- 2017-01-30 SM SM20250086T patent/SMT202500086T1/it unknown
- 2017-01-30 KR KR1020257013550A patent/KR20250065717A/ko active Pending
- 2017-01-30 SG SG11201806401YA patent/SG11201806401YA/en unknown
- 2017-01-30 MX MX2018009227A patent/MX2018009227A/es unknown
- 2017-01-30 BR BR112018015590-0A patent/BR112018015590A2/pt not_active Application Discontinuation
- 2017-01-30 CA CA3013044A patent/CA3013044A1/en active Pending
- 2017-01-30 IL IL286923A patent/IL286923B2/en unknown
- 2017-01-30 KR KR1020187024948A patent/KR102801670B1/ko active Active
-
2018
- 2018-07-26 IL IL260815A patent/IL260815B/en unknown
- 2018-07-27 MX MX2023004443A patent/MX2023004443A/es unknown
-
2021
- 2021-07-29 US US17/388,551 patent/US20220072001A1/en not_active Abandoned
- 2021-12-10 JP JP2021200772A patent/JP7825984B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200583A patent/AU2022200583B2/en active Active
-
2025
- 2025-10-17 US US19/362,118 patent/US20260224575A1/en active Pending
- 2025-10-20 JP JP2025176252A patent/JP2026016502A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3408298T3 (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
| IL285318A (en) | Estrogen receptor modulators | |
| GB201514875D0 (en) | Receptor | |
| GB201518816D0 (en) | Receptor | |
| ZA201700342B (en) | Novel glp-1 receptor modulators | |
| GB201702617D0 (en) | Receptor | |
| IL268263B (en) | Estrogen receptor modulators | |
| IL253411B (en) | History of hydroxyalkyl–piperazine as cxcr3 receptor modulators | |
| IL252565B (en) | New receptor modulators | |
| PT3169452T (pt) | Mecanismo de regulação para sistemas de calibração | |
| GB201711470D0 (en) | Chimeric receptors | |
| IL249160A0 (en) | Crystal forms of an estrogen receptor modulator | |
| EP3224230A4 (en) | Estrogen receptor modulators | |
| GB201701887D0 (en) | Receptor | |
| GB201700926D0 (en) | Receptor | |
| GB201616071D0 (en) | Receptor modulator compounds | |
| GB201616065D0 (en) | Receptor modulator compounds | |
| GB201616072D0 (en) | Receptor modulator compounds | |
| GB201603861D0 (en) | Receptor modulation | |
| GB201512714D0 (en) | Receptor modulator compounds | |
| GB201504285D0 (en) | Receptor modulation |